Medicare Enrolled
Dr. Raghu Nandan, M.D
Hematology & Oncology · Lakewood, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Nandan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nandan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nandan
Dr. Raghu Nandan is a hematology & oncology specialist in Lakewood, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Nandan performed 10,517 Medicare services across 1,493 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nandan received a total of $8,936 from 69 pharmaceutical and/or device companies across 311 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nandan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 28% volume in CA
$8,936 industry payments
Medicare Practice Summary
Medicare Utilization ↗10,517
Medicare services
Top 28% in CA for hematology & oncology
1,493
Unique beneficiaries
$51
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~526 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 3,055 | $18 | $70 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,940 | $102 | $367 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,420 | $68 | $247 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
892 | $106 | $416 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
772 | $8 | $25 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
510 | $0 | $0 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
508 | $8 | $20 |
| Assessment of emotional or behavioral problems An evaluation to identify and understand emotional or behavioral issues. This process involves reviewing symptoms and behaviors to determine the nature of the concerns. |
447 | $4 | $17 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
314 | $12 | $48 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
192 | $146 | $571 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
124 | $154 | $591 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
77 | $26 | $101 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
77 | $117 | $467 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
73 | $0 | $1 |
| New patient office visit, complex (60-74 min) | 64 | $178 | $721 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
29 | $58 | $228 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
23 | $111 | $418 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.7% high complexity
37.6% medium
60.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,936
Total received (2018-2024)
Avg $1,277/year across 7 years
Top 34% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
311
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,504 (95.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$432 (4.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,237
2023
$3,603
2022
$323
2021
$181
2020
$194
2019
$350
2018
$1,049
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$195
PFIZER INC.
$190
Merck Sharp & Dohme LLC
$188
Regeneron Healthcare Solutions, Inc.
$171
Bayer Healthcare Pharmaceuticals Inc.
$138
Exelixis Inc.
$135
Daiichi Sankyo Inc.
$132
PUMA BIOTECHNOLOGY, INC.
$129
AstraZeneca Pharmaceuticals LP
$129
GENZYME CORPORATION
$122
Celgene Corporation
$109
ARRAY BIOPHARMA INC
$108
Karyopharm Therapeutics Inc.
$97
TAIHO ONCOLOGY, INC.
$92
Alexion Pharmaceuticals, Inc.
$87
Novartis Pharmaceuticals Corporation
$86
SOBI, INC
$83
Gilead Sciences, Inc.
$69
PROGENICS PHARMACEUTICALS, INC.
$68
ABBVIE INC.
$68
Incyte Corporation
$66
Pharmacosmos Therapeutics Inc.
$65
Takeda Pharmaceuticals U.S.A., Inc.
$63
Ipsen Biopharmaceuticals, Inc
$50
EMD Serono, Inc.
$45
E.R. Squibb & Sons, L.L.C.
$44
Genentech USA, Inc.
$41
JAZZ PHARMACEUTICALS INC.
$39
Immunocore Limited
$33
SUN PHARMACEUTICAL INDUSTRIES INC.
$31
Stemline Therapeutics Inc.
$30
Sumitomo Pharma America, Inc.
$29
Novocure Inc.
$28
Astellas Pharma US Inc
$24
Tempus AI, Inc
$24
Rigel Pharmaceuticals, Inc.
$24
SpringWorks Therapeutics, Inc.
$22
Lilly USA, LLC
$22
Boehringer Ingelheim Pharmaceuticals, Inc.
$22
Aveo Pharmaceuticals, Inc.
$21
Adaptive Biotechnologies Corporation
$20
Blueprint Medicines Corporation
$20
GlaxoSmithKline, LLC.
$18
Agios Pharmaceuticals, Inc.
$17
MorphoSys, US Inc.
$16
Eisai Inc.
$13
Mirati Therapeutics, Inc.
$13
Top 3 companies account for 17.7% of 2024 payments
All-time payments by company (2018-2024) ›
Allergan Inc.
$674
PFIZER INC.
$445
Incyte Corporation
$386
Medical Device Business Services, Inc.
$365
Merck Sharp & Dohme LLC
$363
Mentor Worldwide LLC
$360
Celgene Corporation
$360
AstraZeneca Pharmaceuticals LP
$334
Janssen Biotech, Inc.
$320
Allergan, Inc.
$305
Bayer Healthcare Pharmaceuticals Inc.
$299
Daiichi Sankyo Inc.
$222
Genentech USA, Inc.
$208
Takeda Pharmaceuticals U.S.A., Inc.
$184
ARRAY BIOPHARMA INC
$175
Karyopharm Therapeutics Inc.
$175
GENZYME CORPORATION
$172
E.R. Squibb & Sons, L.L.C.
$172
Regeneron Healthcare Solutions, Inc.
$171
TAIHO ONCOLOGY, INC.
$164
Exelixis Inc.
$162
Alexion Pharmaceuticals, Inc.
$160
Gilead Sciences, Inc.
$148
Janssen Scientific Affairs, LLC
$145
Novartis Pharmaceuticals Corporation
$133
Ipsen Biopharmaceuticals, Inc
$132
PUMA BIOTECHNOLOGY, INC.
$129
SANOFI-AVENTIS U.S. LLC
$101
CTI BioPharma Corp.
$98
Amgen Inc.
$94
EMD Serono, Inc.
$93
ABBVIE INC.
$89
Blueprint Medicines Corporation
$87
Pharmacosmos Therapeutics Inc.
$87
Lilly USA, LLC
$85
BeiGene USA, Inc.
$85
SOBI, INC
$83
Eisai Inc.
$78
Boehringer Ingelheim Pharmaceuticals, Inc.
$69
PROGENICS PHARMACEUTICALS, INC.
$68
Rigel Pharmaceuticals, Inc.
$64
Genmab U.S., Inc.
$63
Agios Pharmaceuticals, Inc.
$61
Seagen Inc.
$58
Sumitomo Pharma America, Inc.
$55
MorphoSys, US Inc.
$52
Mirati Therapeutics, Inc.
$51
Stemline Therapeutics Inc.
$46
JAZZ PHARMACEUTICALS INC.
$39
Immunocore Limited
$33
Deciphera Pharmaceuticals Inc.
$32
GlaxoSmithKline, LLC.
$32
Foundation Medicine, Inc.
$31
SUN PHARMACEUTICAL INDUSTRIES INC.
$31
Puma Biotechnology, Inc.
$29
ADC Therapeutics America, Inc.
$28
Novocure Inc.
$28
Astellas Pharma US Inc
$24
Tempus AI, Inc
$24
SpringWorks Therapeutics, Inc.
$22
Aveo Pharmaceuticals, Inc.
$21
G1 Therapeutics, Inc.
$21
ImmunoGen, Inc.
$20
Adaptive Biotechnologies Corporation
$20
Jazz Pharmaceuticals Inc.
$16
Catalyst Pharmaceuticals, Inc.
$16
Integra LifeSciences Corporation
$14
Spectrum Pharmaceuticals Inc.
$14
Dova Pharmaceuticals
$11
Top 3 companies account for 16.8% of all-time payments
Associated products mentioned in payments ›
ALLODERM · ALUNBRIG · ARTOURA Breast Tissue Expander · AYVAKIT · BAVENCIO · BILAYER WOUND MATRIX (BWM) · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABOMETYX · COSELA · DARZALEX · DOPTELET · Doptelet · ELAHERE · ENHERTU · EPKINLY · ERLEADA · Elahere · Enhertu · Epkinly · FIRDAPSE · FOTIVDA · FOUNDATIONONE LIQUID CDX · FRUZAQLA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MemoryGel Breast Implants · NATRELLE · NATRELLE SALINE-FILLED BREAST IMPLANTS · Nubeqa · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Optune · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · PYLARIFY · PYRUKYND · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · Rezlidhia · SARCLISA · SCEMBLIX · SYNAGIS · Somatuline Depot · Stivarga · TAGRISSO · TECENTRIQ · TECVAYLI · TFN ADVANCED · TRUMATCH · TUKYSA · Tecentriq · ULTOMIRIS · VENCLEXTA · VERZENIO · Vonjo · XALKORI · XPOVIO · XTANDI · Xtandi · YONSA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
446
Per 100K population
4.5
County median income
$87,760
Nearest hospital
UCI HEALTH-LAKEWOOD
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Nandan is a mixed practice specialist, with above-average Medicare volume (top 28% in CA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Nandan experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Nandan performed 3,055 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nandan receive payments from pharmaceutical companies?
Yes. Dr. Nandan received a total of $8,936 from 69 companies across 311 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nandan's costs compare to other hematology & oncology specialists in Lakewood?
Dr. Nandan's average Medicare payment per service is $51. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nandan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Lakewood
Browse hematology & oncology specialists in Lakewood ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Allergan Inc. Payments to Doctors
See all physicians who received payments from Allergan Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology